Dyadic International (DYAI) Stock Price, News & Analysis

Company Overview

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Key Stats

• Today's Range: $0.92 to $0.98
• 50-Day Range: $0.91 to $1.22
• 52-Week Range: $0.91 to $2.20
• Volume: 112,279 shs
• Average Volume: 54,873 shs
• Market Capitalization: $28.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Dyadic International Stock Analysis - MarketRank™

Dyadic International scored higher than 40% of companies evaluated by MarketBeat, and ranked 654th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dyadic International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Dyadic International has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dyadic International are expected to decrease in the coming year, from ($0.18) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyadic International is -4.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyadic International is -4.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyadic International has a P/B Ratio of 11.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.72% of the float of Dyadic International has been sold short.

Short Interest Ratio / Days to Cover

Dyadic International has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Dyadic International has recently decreased by 10.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyadic International does not currently pay a dividend.

Dividend Growth

Dyadic International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.72% of the float of Dyadic International has been sold short.

Short Interest Ratio / Days to Cover

Dyadic International has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Dyadic International has recently decreased by 10.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Dyadic International this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dyadic International insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.50% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 27.95% of the stock of Dyadic International is held by institutions.

DYAI Stock Analysis - Frequently Asked Questions

How have DYAI shares performed this year?

Dyadic International's stock was trading at $1.75 at the start of the year. Since then, DYAI stock has decreased by 46.8% and is now trading at $0.9310.

How were Dyadic International's earnings last quarter?

Dyadic International Inc. (NASDAQ:DYAI) released its quarterly earnings data on Wednesday, May, 14th. The biotechnology company reported ($0.07) EPS for the quarter. The biotechnology company had revenue of $0.39 million for the quarter. Dyadic International had a negative net margin of 163.94% and a negative trailing twelve-month return on equity of 233.69%.
Read the conference call transcript.

How do I buy shares of Dyadic International?

Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dyadic International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dyadic International investors own include Pfizer (PFE), Enbridge (ENB), Meta Platforms (META), Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DYAI
• CIK: 1213809
• Web: www.dyadic.com
• Phone: (561) 743-8333
• Fax: 561-743-8343
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +544.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.81 million
• Net Margins: -163.94%
• Pretax Margin: -163.77%
• Return on Equity: -233.69%
• Return on Assets: -59.37%

Debt

• Debt-to-Equity Ratio: 5.40
• Current Ratio: 3.98
• Quick Ratio: 3.98

Sales & Book Value

• Annual Sales: $3.49 million
• Price / Sales: 8.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 11.64

Miscellaneous

• Outstanding Shares: 30,090,000
• Free Float: 21,214,000
• Market Cap: $28.01 million
• Optionable: Optionable
• Beta: 0.88